Another key question is why Genzyme walked away from AGTC and their tech before. Does that raise questions in general about their tech and pipeline or was it just something specific to one drug and a move related in part to Sanofi/REGN's close ties?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.